Esomeprazole and aspirin in Barrett’s oesophagus (AspECT): a randomised factorial trial. Lancet 2018; 392: 400–8.

Published: 15th October 2018

Authors: Jankowski JAZ, de Caestecker J, Love SB, Reilly G, Watson P, Sanders S et al.

Conclusion

This multicentre study had a 2 x 2 factorial design and included 2557 patients followed for a median 8.9 years. High-dose esomeprazole with aspirin provided the best protection against death, oesophageal cancer and high-grade dysplasia.

Pubmed Link

Your comments

0 Comments